Joshua Richter, MD

Joshua Richter, MD, is Associate Professor of Medicine in The Tisch Cancer Institute, Division of Hematology and Medical Oncology.

Articles

Cevostamab-Based Regimens Usher In the Next Wave of Bispecific Antibody Strategies in R/R Myeloma: With Joshua Richter, MD

November 28th 2025

Dr Richter discusses the rationale for targeting FcRH5 in myeloma and the evaluation of cevostamab-based combination strategies in this disease.

Dr Richter on the FDA Approval of Linvoseltamab for R/R Multiple Myeloma

July 31st 2025

Joshua Richter, MD, discusses the FDA approval of linvoseltamab for relapsed or refractory multiple myeloma.

Dr Richter on Early Abnormalities Indicative of a Multiple Myeloma Diagnosis

April 15th 2025

Joshua Richter, MD, discusses the identification of early abnormalities that may indicate that a patient has multiple myeloma.

Dr Richter on Goals for Expanding T-Cell–Redirecting Therapies in Myeloma

March 14th 2025

Joshua Richter, MD, discusses the evolution of multiple myeloma treatment in recognition of Myeloma Awareness Month 2025.

Dr Richter on Ongoing Research With Bispecific Antibodies in R/R Multiple Myeloma

March 19th 2024

Joshua Richter, MD, discusses ongoing or upcoming research with bispecific antibodies in relapsed/refractory multiple myeloma.

Dr Richter on Proactive Toxicity Management With Bispecific Antibodies in Myeloma

March 12th 2024

Joshua Richter, MD, discusses the role of bispecific antibody therapy in myeloma and expands on toxicity management for these agents.

Guideline Updates in Multiple Myeloma

March 8th 2024

Joshua Richter, MD, FACP, presents recent National Comprehensive Cancer Network (NCCN) guideline updates in the treatment of multiple myeloma.

Dr Richter on the Optimal Dosing Schedule of Linvoseltamab in Multiple Myeloma

September 29th 2023

Joshua Richter, MD, discusses findings from the phase 1/2 LINKER-MM1 trial (NCT03761108) in multiple myeloma.

Unmet Needs in the Management of Multiple Myeloma

March 11th 2022

Sagar Lonial, MD, provides insight on mechanisms of resistance to CAR T-cell therapies, and the panel shares unmet needs and future directions for the treatment of multiple myeloma.

Role of CAR T Therapies in Newly Diagnosed Multiple Myeloma

March 11th 2022

Ola Landgren, MD, PhD, leads the discussion on the use of cilta-cel and ide-cel in newly diagnosed multiple myeloma and the sequencing of available therapies in transplant-eligible and transplant-ineligible patients.

Novel CAR-T Therapies in Relapsed/Refractory MM and Identifying the Right Patients for CAR-T Therapies

March 11th 2022

Experts discuss emerging BCMA-targeting CAR T-cell therapies under investigation for treating multiple myeloma and barriers to CAR T access.

KarMMa Study in Relapsed/Refractory Multiple Myeloma

March 4th 2022

Katja Weisel, MD, reviews the study results from the KarMMa study evaluating the use of ide-cel in patients with relapsed/refractory multiple myeloma.

CARTITUDE-1 Study in Relapsed/Refractory Multiple Myeloma

March 4th 2022

Ola Landgren, MD, PhD, leads a review of the updated efficacy and safety results and subgroup analysis of the CARTITUDE-1 study for patients with relapsed/refractory multiple myeloma.

Clinical Case 3: A 56-Year-Old Man With Multiple Myeloma

February 25th 2022

Expert hematologist-oncologists review the case of a 56-year-old man with multiple myeloma who received CAR T-cell therapy and share their approaches to treatment.

Treatment Options for Patients Progressing on Belantamab Mafodotin in MM

February 25th 2022

Katja Weisel, MD, reviews potential mechanisms of resistance to belantamab mafodotin in patients with multiple myeloma, and Sagar Lonial, MD, FACP, discusses potential treatment options for patients who progress on belantamab mafodotin.

Ongoing Trials of Belantamab Mafodotin in MM and Optimal Position in Treatment Landscape

February 18th 2022

Joshua Richter, MD, and Sagar Lonial, MD, FACP, review key ongoing clinical trials with belantamab mafodotin in patients with multiple myeloma and the optimal position for belantamab mafodotin in the myeloma treatment landscape.

Managing AEs With Belantamab Mafodotin in Relapsed/Refractory Myeloma

February 18th 2022

Katja Weisel, MD, shares recommended strategies for the prevention and management of potential ocular effects of belantamab mafodotin in multiple myeloma.

Updates From ASH 2021 for Belantamab-based Combinations in Myeloma

February 11th 2022

Ola Landgren, MD, PhD, and Joshua Richter, MD, review belantamab mafodotin–based combination regimens currently being evaluated in relapsed/refractory multiple myeloma, as well as the newly diagnosed setting, as presented at the recent ASH 2021 meeting.

Role of Belantamab Mafodotin in R/R MM

February 11th 2022

Sagar Lonial, MD, reviews key takeaways from the DREAMM-2 trial, and Katja Weisel, MD, comments on the potential use of belantamab mafodotin in the early relapse setting for multiple myeloma.

Clinical Case 2: 59-Year-Old Woman With R/R MM

February 4th 2022

Experts in hematology-oncology review the case of a 59-year-old woman with relapsed/refractory multiple myeloma and discuss their thoughts on the given treatment approach.